Title:
COMPOUND HAVING ANTICANCER ACTIVITY, AND PREPARATION METHOD AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2018/090975
Kind Code:
A1
Abstract:
A compound represented by a formula I structure, and a preparation method and application in the treatment of cancer thereof are disclosed. The compound has an inhibitory effect on a plurality of cancer cells, and may be biologically transformed into the active drug Linifanib in vitro (in liver homogenate and spleen homogenate) so as to inhibit the proliferation of tumor cells, especially liver cancer cells, at a lower dose.
Inventors:
GONG JOHN (CN)
LIN YIHUI (CN)
LI FENGQING (CN)
TANG FANGQIANG (CN)
LIN YIHUI (CN)
LI FENGQING (CN)
TANG FANGQIANG (CN)
Application Number:
PCT/CN2017/111653
Publication Date:
May 24, 2018
Filing Date:
November 17, 2017
Export Citation:
Assignee:
3D MEDICINES LTD (CN)
International Classes:
C07D231/56; A61K31/416; A61P35/00
Foreign References:
| CN1826324A | 2006-08-30 | |||
| CN101754955A | 2010-06-23 |
Other References:
WU, X. Y.: "Molecular docking and 3D-QSAR study on 4-(lH-indazol-4-yl) phenylamino and aminopyrazolopyridine urea derivatives as kinase insert do- main receptor (KDR) inhibitors", JOURNAL OF MOLECULAR MODELING, 22 June 2011 (2011-06-22), XP035018246, ISSN: 0948-5023, DOI: doi:10.1007/s00894-011-1146-9
J. CLIN. ONCOL., vol. 33, 2014, pages 172 - 179
See also references of EP 3543228A4
J. CLIN. ONCOL., vol. 33, 2014, pages 172 - 179
See also references of EP 3543228A4
Attorney, Agent or Firm:
HYLANDS LAW FIRM (CN)
Download PDF: